NCT03505320: An ongoing trial by Astellas Pharma Global Development, Inc.
This trial is ongoing. It must report results 1 year, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03505320 |
|---|---|
| Title | A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination With Chemotherapy and/or Immunotherapy in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma Whose Are Claudin (CLDN) 18.2 Positive |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 29, 2018 |
| Completion date | July 31, 2026 |
| Required reporting date | July 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |